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http://www.biomedcentral.com/1471-2350/14/91RESEARCH ARTICLE Open AccessSplice site SNPs of phospholipase PLCXD3 are
significantly associated with variant and sporadic
Creutzfeldt-Jakob disease
Matthew T Bishop1*, Pascual Sanchez-Juan2 and Richard SG Knight1Abstract
Background: Variant Creutzfeldt-Jakob disease is an infectious, neurodegenerative, protein-misfolding disease, of
the prion disease family, originally acquired through ingestion of meat products contaminated with bovine
spongiform encephalopathy (BSE). Public health concern was increased by the discovery of human-to-human
transmission via blood transfusion. This study has verified a novel genetic marker linked to disease risk.
Methods: SNP imputation and association testing indicated those genes that had significant linkage to disease risk
and one gene was investigated further with Sanger resequencing. Results from variant Creutzfeldt-Jakob disease
were compared with those from sporadic (idiopathic) Creutzfeldt-Jakob disease and published controls.
Results: The most significant disease risk, in addition to the prion protein gene, was for the phosphatidylinositol-specific
phospholipase C, X domain containing 3 (PLCXD3) gene. Sanger resequencing of CJD patients across a region of
PLCXD3 with known variants confirmed three SNPs associated with variant and sporadic CJD.
Conclusions: These data provide the first highly significant confirmation of SNP allele frequencies for a novel CJD
candidate gene providing new avenues for investigating these neurodegenerative prion diseases. The phospholipase
PLCXD3 is primarily expressed in the brain and is associated with lipid catabolism and signal transduction.
Keywords: Prion disease, Infection, Neurodegeneration, Susceptibility, PhospholipaseBackground
Prion diseases are a family of fatal neurodegenerative
diseases that can be idiopathic, acquired through infec-
tion, or associated with genetic mutations; Creutzfeldt-
Jakob disease (CJD; OMIM 123400) being the main
human disease. They are characterised by the tissue
deposition of an abnormal misfolded form of the host-
encoded prion protein (PrP), termed PrPSc. The poten-
tially infectious nature of prion disease makes it unique
amongst other protein-misfolding neurodegenerative hu-
man diseases such as Alzheimer’s disease. In this study,
patient cohorts were from the idiopathic sporadic CJD
(sCJD) and from the acquired variant CJD. Sporadic CJD
occurs worldwide with an annual mortality rate of ap-
proximately 1 per million per year, presenting typically* Correspondence: m.bishop@ed.ac.uk
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reproduction in any medium, provided the oras a rapidly progressive encephalopathy in the middle-
aged and elderly, with conclusive diagnosis from neuro-
pathological examination of the brain (showing spongi-
form change, gliosis, neuronal loss, and the hallmark
deposition of PrPSc). Variant CJD was first described in
1996, arising initially from food contamination with bo-
vine spongiform encephalopathy (BSE) infectious mater-
ial [1]. Variant CJD has since been diagnosed in 176
individuals from the United Kingdom and 51 from other
countries, and has recently been associated with infec-
tion via blood transfusion. In relation to sCJD, variant
CJD generally affects a younger age group, presents dif-
ferently (with predominantly psychiatric early features)
and with a slower clinical progression. Both sCJD and
vCJD share similar pathological features representative of
a prionopathy, however vCJD has some additional specific
neuropathological features [2]. Prion protein gene (PRNP)
analysis has shown that all examined definite and probable
cases of vCJD (diagnostic criteria [http://www.cjd.ed.ac.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(MM) at codon 129 (dbSNP reference rs1799990). Spor-
adic CJD patients have an over-abundance of homozy-
gotes for both alleles (59.5% MM, 21.4% MV, and 19.1%
VV) when compared with UK genotype frequencies for
controls (44.1% MM, 44.5% MV, and 13.4% VV) [3].
After a peak in 2000, the annual mortality rate for vCJD
has since fallen, with total future cases at an estimated
median level of 390 for the years 2010 to 2179 [4]. The
potential for a silent epidemic of asymptomatic infec-
tion lead to tissue screening programs looking for PrPSc
deposition in appendices or tonsils (presymptomatic
lymphoreticular involvement is found in vCJD [5,6]).
The most recent appendix survey indicates that 1 in
2000 individuals in the United Kingdom may have
asymptomatic vCJD infection [7].
Identification of a genetic component to risk of vCJD
infection may explain why relatively few people have
died from vCJD despite significant dietary exposure
in the UK [8] and could give an insight into the patho-
logical processes specific to this disease. Currently
the only non-PRNP gene targets found have limited
confirmed associations to vCJD: cathepsin D [9], MT-
MR7 [10], and RARB and STMN2 [11]. The aim of
this study was to take the genome-wide association
(GWAS) data that we have previously published [10]
and impute additional SNPs based on published gen-
ome genotype data to uncover further candidate genes
which would then be resequenced in vCJD and sCJD
populations for validation.
Methods
Imputation
Imputation was carried out using the following software:
 R programming environment (http://www.R-project.org)
 R package GenABEL (http://www.genabel.org) [12]
 minimac (http://genome.sph.umich.edu/wiki/
Minimac) [13]
 MACH (Markov Chain based haplotyper; http://
www.sph.umich.edu/csg/abecasis/MACH/index.
html) [14]
 PLINK (Version 1.07-1, http://pngu.mgh.harvard.
edu/purcell/plink/) [15]
Affymetrix 500K chip SNP genotype data from our
previous publication [10] were uploaded into the
GenABEL R package. This included 85 vCJD patients
and 1481 Wellcome Trust Case–control Consortium
(www.wtccc.org.uk) samples. ‘QTSCORE’ analysis found
those SNPs with lower p-values than those from the
prion protein gene and these were removed from sub-
sequent analysis (leaving 287545). These SNPs had
already been shown, or presumed, to be false positivesby genotyping in our earlier publication [10]. The
chromosome data were prephased (haplotyped) using
the minimac command line protocol ‘mach1’ with the
parameters: Iterations of the Markov sampler to use for
haplotyping – 20; Haplotypes to consider during each
update – 200; Repeated iterations for when random
(but plausible) sets of haplotypes for each individual
should be drawn – 5. The MACH operation followed
using the recommended command line operations to-
gether with the 1000 Genomes (www.1000genomes.org)
haplotype dataset for the reference SNP data (MACH
website file: 2010-06.CEU.map.tgz). Due to computing
power limits a subset of the control samples was used
for these analyses. Data for all 85 vCJD patients, and
665 of the 1481 controls were used. For the large
chromosome 2 only 415 controls were used. This oper-
ation generated a total of 6858238 SNPs across the gen-
ome to be used for association testing.
Association
Association testing using the PLINK software suite
followed the quality control guidance given by Anderson
et al [16]. The chromosome specific MACH output
files were converted into PED/MAP format files using
the Perl script ‘convert_mach.pl’ from GenGen (Im-
putation Helper; www.openbioinformatics.org/gengen),
then merged and converted to the PLINK binary format
(bim, bed, and fam).
QC Screening
 No individuals had elevated missing data rates
(>3%).
 Five individuals (one vCJD patient and four
controls) were excluded as they had heterozygosity
at more than 3 × standard deviation of the
calculated heterozygosity rate.
 The ‘missing rate’ was calculated for each SNP, and
with a threshold of >10% failure, 4626404 SNPs
were removed from the subsequent analysis.
 The difference in genotype call rates between cases
and controls gave a total of 337307 SNPs with p <
0.00001 significance, that were removed.
 PLINK association testing removed those markers
that were not in Hardy Weinberg equilibrium
(151347), those that fail a genotype ‘missingness test’
(4289134; GENO > 0.1), and those failing a minor
allele frequency test (3800790; MAF < 0.01).
 This QC analysis left 1544357 SNPs for the association
analysis on 84 vCJD and 661 control samples.
Association testing, with adjustment for multiple test-
ing, using PLINK showed no evidence of population
stratification (genomic inflation factor is 1, with mean
chi-squared statistic 0.997035).
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The PLCXD3 gene intron 1/exon 2 boundary (847 bp) was
amplified by PCR using forward (5’-gtggctcatttgagggagag-
3’) and reverse (5’-atttgaggtttccccctgac-3’) primers (Eurofins
MWG Operon, UK). PCR products were sequenced using
the reverse primer (5’-catttccgcatgagcttttt-3’) and BigDye
Terminator v3.1 Cycle Sequencing kit (Invitrogen, UK) on
an ABI3130 capillary sequencer.
Resequencing statistics
Fisher’s Exact Test was used to compare allele and geno-
type frequencies for the PLCXD3 SNPs.
Splice site motif analysis
The online tool SVM-BPfinder (http://regulatorygenomics.
upf.edu/Software/SVM_BP/) was used to predict the effects
of the SNP variation on the recognition sites for the branch
point and polypyrimidine tract motifs of the 3’ splice site.
The following sequence for the 3’ end of intron 1 was
uploaded to the website: 5’-GCAAGAGGGAAAGAAG[K]
TGGGAAGGG[M]AAAGACGTGGAAATTAACCACAC
TATGCCTTGT[W]ATTCTCCTAG-3’ (SNPs in brackets).
Eight ‘fasta’ format files were used covering all possible
combinations of alleles for the three SNPs.
Ethical consent
Consent was given for research and the study is covered
by approval from the Lothian Health Board, Lothian Re-
search Ethics Committee (reference MCO/103/90). Writ-
ten informed consent for research was obtained from each
patient or a family relative.
Sample collection
DNA used in this study was extracted from blood samples
taken from patients whilst under clinical investigation.
Ethnic origin
Both vCJD and sCJD populations were sourced from
UK resident patients. The majority are Caucasian with
three vCJD and three sCJD patient described as non-
Caucasian. For control samples, the 1000 Genome re-
sults are from individuals of European ancestry and theFigure 1 Diagram showing the DNA sequence from the intron 1/exon
under investigation.Exome Variant Server data are from individuals of Euro-
pean American ancestry.
Results
The initial input data for this study were 287545 Affy-
metrix 500K chip genotypes [10] and following imputation
and QC screening this increased to a total of 1544357
SNPs for PLINK association testing. The most significant
SNPs were on chromosome 20 within close proximity of
the prion protein gene (PRNP) (value p = 1.484e-05). The
next most significant region was on chromosome 5 at the
PLCXD3 (phosphatidylinositol-specific phospholipase C,
X domain containing 3) gene locus with p-values just sig-
nificant after Bonferroni correction (value p = 0.0236). The
next SNPs were on chromosome 9 (Gene: GLIS3 (GLIS
family zinc finger 3)), chromosome 12 (near TSPAN8
(tetraspanin 8)), and chromosome 1 (near RGS4 (regulator
of G-protein signalling 4)) although these were not signifi-
cant after Bonferroni correction [see Additional file 1:
Table S1].
The PLCXD3 gene was chosen for Sanger resequen-
cing and using data from the Exome Variant Server
(http://evs.gs.washington.edu/EVS/) we selected a re-
gion near the splice junction of intron 1 and exon 2
(genome assembly GRCh37 position Chr5:41382626-
41382697) that had two informative SNPs with high
minor allele frequencies (rs319013 MAF 35.45%;
rs76547469 MAF 5.39%). In close proximity to the two
chosen SNPs was a third variant (rs545358) that was
not on the Exome Variant Server but was included in
subsequent genotype analysis (Figure 1). 120 vCJD and
109 sCJD patients were sequenced and the results com-
pared with European control data from 1000 Genomes
and the Exome Variant Server. All three SNPs show sta-
tistically significant differences between disease and
control samples, and rs545358 had higher risk allele
frequencies in vCJD than sCJD (Table 1).
The online splice site analysis tool (SVM-BPfinder) out-
put predicted that the most suitable polypyrimidine tract
splice motif was obtained when ‘T’ was present at SNP
rs76547469 (with adenosine present the polypyrimidine
tract is not recognised), and with the branch point adenosine2 border of the PLCXD3 gene showing positions of the SNPs
Table 1 Summary of resequencing data with Fisher’s test analysis of variant CJD, sporadic CJD and controls
Genotype Count
rs545358 rs319013 rs76547469
GG:GT:TT CC:CA:AA TT:TA:AA
sCJD (n = 109) 15:3:91 48:24:37 99:2:8
vCJD (n = 120) 49:3:68 52:21:47 110:3:7
1000 Genomes (n = 379) 1:41:337 n/a n/a
Exome Variant Server (n = 4241) n/a 599:1894:1748 3838:428:17
Fisher's Test Results for sCJD and vCJD versus Online Controls
Test dbSNP Identifier Genotype/Allele Comparison p value Odds io 95% Confidence Interval Significance1
sCJD vs. vCJD
rs545358 G vs. T 2.04E-10 0.246 0.151 - 0.393 ***
GG vs. TT 6.46E-06 0.230 0.110 - 0.459 ***
GG vs. GT 0.172 0.312 0.038 - 2.579
rs319013 C vs. A 0.5738 1.126 0.767 - 1.655
CC vs. AA 0.6568 1.172 0.629 - 2.190
CC vs. CA 0.5933 0.809 0.375 - 1.734
rs76547469 T vs. A 0.7255 0.847 0.398 - 1.795
TT vs. AA 0.7906 0.788 0.234 - 2.589
TT vs. TA 1 1.348 0.151 - 16.444
sCJD vs. Controls
rs545358 G vs. T 2.01E-05 2.962 1.769 - 4.923 ***
GG vs. TT 2.69E-09 55.00 8.253 - 2315.479 ***
GG vs. GT 2.30E-10 163.7 17.131 - 8175.872 ***
rs319013 C vs. A 4.69E-08 2.134 1.615 - 2.827 ***
CC vs. AA 4.22E-09 3.783 2.387 - 6.038 ***
CC vs. CA 6.73E-14 6.318 3.758 - 10.882 ***
rs76547469 T vs. A 0.07015 0.633 0.386 - 1.101
TT vs. AA 1.61E-07 0.055 0.022 - 0.151 ***
TT vs. TA 0.003525 5.519 1.478 - 46.367 **
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Table 1 Summary of resequencing data with Fisher’s test analysis of variant CJD, sporadic CJD and controls (Continued)
vCJD vs. Controls
rs545358 G vs. T < 2.2e-16 12.038 7.957 - 18.471 ***
GG vs. TT < 2.2e-16 237.889 39.562 - 9180.580 ***
GG vs. GT < 2.2e-16 530.747 60.122 - 16384.000 ***
rs319013 C vs. A 1.25E-06 1.894 1.452 - 2.471 ***
CC vs. AA 3.56E-08 3.227 2.108 - 4.951 ***
CC vs. CA < 2.2e-16 7.834 4.593 - 13.812 ***
rs76547469 T vs. A 0.2474 0.748 0.452 - 1.318
TT vs. AA 3.67E-06 0.070 0.027 - 0.203 ***
TT vs. TA 0.005828 4.088 1.353 - 20.212 **
Significance * 0.05 - 0.001 ** 0.001 - 0.0001 *** <0.0001
1 Significance: * 0.05-0.001; ** 0.001-0.0001; *** <0.0001.
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Table S2].
Discussion
Three intronic SNPs in the PLCXD3 gene (rs319013,
rs76547469, and rs545358) are associated with increased
risk of CJD compared with published healthy control
data and represent the first major association of a non-
PRNP candidate gene. These SNPs lie at the junction of
intron 1 and exon 2 in close proximity to the splice site
motifs. Exon 2 codes for the main active structural do-
main of PLCXD3 and therefore any alteration to the
functioning of the spliceosome at this part of the gene
could have a significant impact on the activity of the
whole protein. Using the online tool ‘SVM-BPfinder’ we
found that with the replacement of thymidine with
adenosine at SNP rs76547469 the polypyrimidine tract
motif is not recognised and therefore this change is
likely to weaken the spliceosome activity. Further inves-
tigation into potential PLCXD3 protein structural alter-
ations and the role of the protein in CJD pathology are
now needed to clarify the association between the dis-
ease phenotype and the presence of these SNP risk
alleles. It is proposed that PLCXD3 would have an effect
on the pathological pathways of CJD rather than having
a direct molecular interaction with the specific mis-
folding of prion protein.
Phospholipase C X-domain containing proteins (PLCXDs)
are a subtype of the phosphatidylinositol-specific phos-
pholipase C (PI-PLC) protein family that is a key compo-
nent of eukaryotic signal transduction with a role in
inositol phospholipid metabolism. PI-PLC enzymes are
receptor-regulated phosphodiesterases that control cel-
lular processes by regulation of cytosolic calcium and/or
protein kinases. They regulate hormones, growth factors,
and neurotransmitters by generating the calcium-regulator
inositol-1,4,5-triphopshate (InsP3) and the membrane-
bound protein kinase C activator diacylglycerol (DAG)
[17]. The PI-PLC family has a characteristic pairing of X
and Y-domains that together form a barrel-like second-
ary structure for the catalytic site. In contrast, PLCXD
proteins have only the X-domain, as also seen in bac-
teria. Studies of bacterial PI-PLC proteins indicate that
for PLCXD3 the absence of the Y-domain and other
protein motifs suggests it has a role in calcium inde-
pendent phosphatidylinositol metabolic processes with
a preference for cleavage of only PI [18]. So far at least
three isoforms of PLCXD proteins have been identified:
PLCXD1, PLCXD2, and PLCXD3. These are proposed
to have distinct functions due to their varied tissue dis-
tribution and cellular location but are all likely to be ac-
tive phosphodiesterases as they increase the turnover of
inositol phosphate (InsP) [19]. In a cell culture model
PLCXD3 was found in cytoplasmic and perinuclearvesicles and from analysis of RNA levels it was ex-
pressed in a wide range of tissue types suggesting a po-
tential key cellular role, with predominant expression
seen in the brain [19]. The role of PLCXD3 in neurode-
generative disease is as yet unknown, although PI-PLC
and specifically Ca2+ homeostasis have been associated
with neurodegeneration. Torres et al [20] discussed the
role of calcium homeostasis and protein folding at the
endoplasmic reticulum in prion disease and highlighted
a number of relationships between calcium ion levels
and the abnormal form of the prion protein. The gen-
etic association seen in our data may provide a novel
target to understand these pathways. It is of significant
importance that the functional pathways which include
PLCXD3 may also involve MTMR7, another phospha-
tidylinositol phospholipase that was the primary candi-
date gene from our initial GWA study [10].
Conclusions
Our data provide the first highly significant genetic asso-
ciation outside the prion protein gene locus for the va-
riant and sporadic forms of CJD. We hope that the
PLCXD3 gene locus will now become a focus for more
studies in these diseases. To investigate the mechanisms
that may exist in both acquired and idiopathic forms of
CJD in relation to the PLCXD3 protein we aim to iden-
tify the expression level, localisation, and forms of
PLCXD3 in disease tissue and non-CJD controls.
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